Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission

This cohort study evaluates all products targeted by the Federal Trade Commission from 2023 to 2025 and analyzes how delistings have impacted periods of patent protection.

Authors

Institutions

Publication Details

Journal
JAMA Internal Medicine
Published
2026-05-11
DOI
https://doi.org/10.1001/jamainternmed.2026.0980
Primary Topic
Intellectual Property and Patents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission

Jennifer Leon, Aaron S. Kesselheim, S. Sean Tu, William B. Feldman
JAMA Internal Medicine
Intellectual Property and Patents
article

Delisting of Pharmaceutical Patents Challenged by the Federal Trade Commission

Jennifer Leon, Aaron S. Kesselheim, S. Sean Tu, William B. Feldman
article en

Abstract

This cohort study evaluates all products targeted by the Federal Trade Commission from 2023 to 2025 and analyzes how delistings have impacted periods of patent protection.

JAMA Internal Medicine
University of Notre Dame (US), Brigham and Women's Hospital (US), Harvard University (US), University of Alabama (US), Pulmonary and Allergy Associates (US)
Openalex Percentile: Top 5%
Intellectual Property and Patents
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.